TransCode Therapeutics (NASDAQ: RNAZ) has released updated clinical data from its Phase 1a trial of TTX-MC138, a novel RNA therapeutic for advanced solid tumors. The results, as of September 1, show that 10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as their best overall response. Six patients remained progression-free at three months, and three continued progression-free at six, nine, and twelve months. The disease control rate was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1. These findings are particularly significant for patients with relapsed or refractory, unresectable locally advanced or metastatic solid tumors, who often have limited treatment options. The ability to achieve stable disease and prolong progression-free survival in this difficult-to-treat population highlights the potential of TTX-MC138 to address a critical unmet need in oncology.
A post-hoc Growth Modulation Index (GMI) analysis further supports the drug's activity: six of 15 evaluable patients (40%) achieved a GMI greater than 1.3, indicating a progression-free interval at least 30% longer than with their immediately preceding therapy. This suggests that TTX-MC138 may offer a meaningful clinical benefit compared to prior treatments. Importantly, the safety profile remains favorable. As of September 1, a total of 98 doses had been administered, with no dose-limiting toxicities reported and no treatment-emergent adverse events leading to treatment discontinuation, even at the highest evaluated dose of 4.8 mg/kg. This is a crucial finding, as safety is a primary concern in early-phase oncology trials. The absence of dose-limiting toxicities supports further dose escalation and exploration of optimal dosing strategies.
Exploratory RNA-sequencing analysis identified treatment-associated immune effects that the company believes support the observed clinical activity. While these biomarker findings require confirmation in larger studies due to the small sample size, they provide a potential mechanistic rationale for the drug's efficacy. TransCode is now evaluating dose-expansion strategies and plans to continue assessing safety, pharmacokinetics, pharmacodynamics, and antitumor activity. For a full press release, visit https://ibn.fm/mIBZR. The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. This announcement matters because it demonstrates the potential of RNA therapeutics to make a tangible difference in hard-to-treat cancers. With limited options for patients with advanced solid tumors, any new therapy that can provide disease control and prolong survival without significant toxicity is a major step forward. The data also validate the microRNA-10b approach, which could open doors for additional RNA-based therapies. For investors, the results de-risk the program and support continued development, potentially leading to partnerships or accelerated pathways. As the company moves into dose expansion, the focus will be on confirming these early signs of efficacy in larger cohorts and further characterizing the biomarker profile. If subsequent trials replicate these findings, TTX-MC138 could become an important addition to the oncology arsenal.
BioMedWire, a specialized communications platform for the biotech and life sciences sectors, is part of the Dynamic Brand Portfolio at IBN. The platform provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
